A sample size of 20 hospitals and 33 chemists was chosen from the region. The survey method chosen was pharmacy to pharmacy by conducting personal interview, the data collection was extended for over 45 days and 20 pharmacy in-charge and 33 chemists were interviewed and asked questions regarding their awareness, availability, prescriptions and the sale of cardiovascular injections (containing Amiodaron and Enoxaparin) like Amiodaron (Sanofi), Tachyre (Cipla), Clexane (Aventis), LMWX (Nicholas), Flothin (Ranbaxy), Enclex (cipla) etc. and Cardiovascular medicines (containing Atorvastatin, Metoprolol, Torsemide and Telmisartan). It is found that on what doctors & hospitals would company focus. The data collected originally was on weekly basis and for the purpose of analysis of all the results on monthly basis. The research brought out the fact like the awareness level of the above brand, market coverage, market potential, sale, important hospitals and important doctors who prescribed these cardiovascular drugs. Cipla, originally founded as the Chemical, Industrial & Pharmaceutical Laboratories is a prominent Indian pharmaceutical industry, best-known outside its home country for producing low-cost anti-AIDS drugs for HIV-positive patients in developing countries. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide. Among the hundreds of generic medications it produces for international distribution are atorvastatin, amlopidine, fluoxetine, venlafaxine hydrochloride and metformin. The company was founded in 1935 by Khwaja Abdul Hamied, and its chairman today is Yusuf Hamied (b. 1936), the founder's eldest son. The journey began in 1973, when Cipla took the initiative to launch the 1st β-blocker in India, Propranalol under the brand name CIPLAR. Since then, over the last 3 decades, Cipla Vitalis has continued to excel in the field of cardiovascular therapies with new innovative products & services.
[...] ORG-IMS, the largest market intelligence company in India focusing on the healthcare sector, tracks sales of Indian pharmas on a monthly basis, through over 3,000 stockiest and 6,000 doctors. “Indian companies are increasing their share in the domestic market mainly due to increased number of high value new introductions, though the numbers of new introductions have reduced recently,” Shailesh Gadre, managing director, ORG-IMS, said in an interview last week. Cipla's growth was powered by positive growth in their existing portfolio, especially its respiratory products. [...]
[...] Research Objective My research objective is comparative study of the market potential of cardiovascular molecules in PHARMACUETICAL INDUSTRY. The molecules are Enoxaparin Amiodaron Atorvastatin Metoprolol Torsemide Telmesartan 1. To find out whether the chemist are aware about these molecules or not? 2. To find out which brand of particular molecule is being prescribed by doctors most and why? Amiodaron Systematic (IUPAC) name (2-butylbenzofuran-3-yl) [4-(2-diethylaminoethoxy) 3,5-diiodo-phenyl]- methanone (as the hydrochloride salt) Amiodarone is an antiarrhythmic agent (medication used for irregular heart beat) used for various types of tachyarrhythmias (fast forms of irregular heart beat), both ventricular and supraventricular (atrial) arrhythmias. [...]
[...] Cipla's Export Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products drugs to more than 160 countries including the U.S., and a number of countries in Europe, Africa, Australia, Latin America and the Middle East. Cipla shipped products worth more than Rs.10,500 million last year. Exports amounted to more than Rs.10,500 million. Cipla exports. Cipla also offers technology for products and processes. Recently, Cipla entered agreement with Pentech Pharma of USA for marketing a range of generic products for American market. [...]
[...] of Metoprolol strips ic) ) Medical Store Nagar Goel rk) Soni Jain rk) rk) Soni Bhat las) las) Bhat las) (Micro) Sharma (Cipla) Goel a Singhania Sharma Sharma Seth Goel p Singh ) Sharma Garg Data Analysis of Cardiac injectibles (Enoxaparin & Amiodaron) in Hospitals, Ghaziabad Name of the Institute Sales (in vials) Sales in Percentage Narendra Mohan Hospital Yashoda Hospital Ganesh Hospital Paras Hospital Chandralaxmi Hospital Sarvodaya Hospital,Vaishali Avantika Hospital Yashoda Hospital.Kaushambi Santosh Hospital Shivam Hospital Sarvodaya Hospital,Kavinagar Vasundhara Hospital Total A comparative study of most sold cardiac injectibles (Amiodaron & Enoxaparin) in different Institutes in Ghaziabad Data Analysis of Cardiac injectibles (Enoxaparin & Amiodaron) in Hospitals, Noida Name of the Institute Sales (in vials) Sales in Percentage Fortis Hospital Metro Hospital Max Hospital Kailash Hospital Vinayak Hospital Prakash Hospital Sumitra Hospital Ojjus Goodwill Hospital Total A comparative study of most sold cardiac injectibles (Amiodaron & Enoxaparin) in different Institutes in Noida Comparison between most sold cardiovascular molecules Atorvastatin( 46.67 Metoprolol( 37.12 Torsemide( 35.30 ) & Telmisartan( 33.88 ) Analysis: 1. [...]
[...] The CFC- free products have a huge export potential .The inhaler therapy is preferred to tablets since the dose required is about 10 of the oral dose. Moreover, the drug directly goes to the lung and gives instantaneous relief to the patient. Cipla is putting up a dedicated facility at Kurkumbh at a capital outlay of Rs Cr. for the manufacture of inhalers. We feel that the company will be able to maintain a leadership position due to the entire range of inhalers and with the advantage of economies of scale. [...]
Online readingwith our online reader
Content validatedby our reading committee